About Mitochondrial amidoxime reducing component 2
Mitochondrial amidoxime reducing component 2 (MTARC2) is a protein
from Homo sapiens identified by UniProt accession
Q969Z3, 335 residues long.
MolForge cross-references it against 0 known binders and
82 disease associations.
Target properties
| Protein name | Mitochondrial amidoxime reducing component 2 |
|---|
| UniProt accession | Q969Z3 |
|---|
| Gene | MTARC2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 335 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (82)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.11
- diastolic blood pressure · score 0.10
- body height · score 0.10
- Visual loss · score 0.10
- plasma protein metabolism disease · score 0.09
- neutrophil percentage of leukocytes · score 0.09
- hepatocellular carcinoma · score 0.09
- high density lipoprotein cholesterol measurement · score 0.08
- BMI-adjusted waist circumference · score 0.08
- reticulocyte count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q969Z3-F1 | alphafold | PREDICTED | 91.21 | — |
Amino-acid sequence (335 residues)
MGASSSSALA RLGLPARPWP RWLGVAALGL AAVALGTVAW RRAWPRRRRR LQQVGTVAKL WIYPVKSCKG VPVSEAECTA MGLRSGNLRD RFWLVIKEDG HMVTARQEPR LVLISIIYEN NCLIFRAPDM DQLVLPSKQP SSNKLHNCRI FGLDIKGRDC GNEAAKWFTN FLKTEAYRLV QFETNMKGRT SRKLLPTLDQ NFQVAYPDYC PLLIMTDASL VDLNTRMEKK MKMENFRPNI VVTGCDAFEE DTWDELLIGS VEVKKVMACP RCILTTVDPD TGVIDRKQPL DTLKSYRLCD PSERELYKLS PLFGIYYSVE KIGSLRVGDP VYRMV
Explore Mitochondrial amidoxime reducing component 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets